Eager to more tightly control costs to consumers of emerging medical therapies, Japanese authorities are discussing implementing rules to regulate prices on regenerative medicine products At a February 20, 2019 meeting of the Ministry of Health, Labor and Welfare (MHLW), officials for... Read More
China’s health insurance regulator in October added 17 anti-cancer drugs to the list of those already covered by its national medical insurance system. The approval of the therapies is part of a series of moves by the government to make cancer treatment... Read More
U.S. pharmaceuticals may stand to gain if revisions to a longstanding trade agreement between the United States and South Korea, announced in September, are approved and implemented. The updates to the U.S.-Korea Free Trade Agreement (KORUS) include a provision to include American... Read More
Many Chinese citizens today are demanding better drugs and treatments for diseases. IQVIA Holdings predicts that the China drug market will grow by 30% over the next few years, reaching $170 billion in sales. Last year, China added about 100 Western drugs... Read More
Under popular pressure to boost the affordability of cancer medications, China’s health insurance regulator announced in August that it will add a range of cancer drugs to the list of those already covered by the national medical insurance system. At the same... Read More
In a step forward for the advancement of health research in South Korea, patients participating in clinical trials aimed at advancing public health are now covered by the country’s vaunted national health insurance system. The change went into effect on May 1.... Read More
A claim by the leading U.S. pharmaceutical industry lobby that South Korea unfairly favors its own drug manufacturers over foreign firms is receiving strong pushback by the Korean government. Earlier this year, Pharmaceutical Research and Manufacturers of America (PhRMA) argued to the... Read More
This article was originally published on MedTech Intelligence. Last year, Research and Markets released a report projecting that China’s in vitro diagnostics (IVD) market is likely to triple in size before 2022. This growth is driven by an aging population, a growing... Read More
Up until now, China has only had a few Diagnosis-Related Groups (DRGs), and they have not been a factor in China’s healthcare scheme. However, in February 2018, China’s Ministry of Human Resources and Social Security (MoHRSS) released a list of 130 diseases... Read More
Following the example of the U.S. FDA's Orphan Drug Act established in 1983, some Asian countries have developed orphan drug legislation, such as Singapore's Orphan Drug Exemption to the Medicines Act and Japan's Orphan Drug Amendment to the Pharmaceutical Affairs Law. While... Read More